心房颤动合并急性冠状动脉综合征的抗血栓治疗进展

Research Progress of Antithrombotic Therapy in Patients with Concomitant Atrial Fibrillation and Acute Coronary Syndrome

心房颤动和急性冠状动脉综合征常合并存在。口服抗凝治疗对于预防心房颤动相关卒中和体循环栓塞至关重要,而双联抗血小板治疗则是治疗急性冠状动脉综合征的基石。对于心房颤动合并急性冠状动脉综合征患者,理论上应接受三联抗血栓治疗,而出血风险也会显著增加。对于此类患者如何平衡缺血和出血风险成为难题,现就心房颤动合并急性冠状动脉综合征的抗血栓治疗研究进展做一综述。

Atrial fibrillation （AF） and acute coronary syndrome （ACS） is often in combination. Oral anticoagulant therapy is crucial to prevent the incidence of AF-related stroke and systemic embolism, and dual antiplatelet therapy is the cornerstone for the treatment of ACS. Thus, AF patients presenting with ACS have indications for triple antithrombotic therapy, which wiU increase the risk of bleeding signifi- cantly. How to balance both the risk of ischemia and hemorrhage is a conundrum in clinical practice. In this review, the latest evidence on the risks and benefits of antithrombotic therapy in patients with concomitant AF and ACS is summarized.